To evaluate the prognostic significance of Wilms' tumor gene 1 (WT1) expression for monitoring minimal residual disease and predicting relapse in patients with acute leukemia (AL) following allogeneic hematopoietic SCT (allo-HSCT), the WT1 expression levels of 138 AL patients were measured using real-time quantitative reverse transcription PCR at designed time points after allo-HSCT. All patients were divided into four groups based on the HSCT outcomes and intervention application. A low level of WT1 expression following HSCT indicated a low risk of relapse, whereas WT1 expression 41.05% was indicative of a higher probability of relapse. Only the advanced stage of disease (hazard ratio (HR) ¼ 2.73; 95% confidence interval (CI) ¼ 1.337-5.573, P ¼ 0.006) and a WT1 expression X0.60% (HR ¼ 4.774; 95% CI ¼ 2.410-9.459, P ¼ 0.000) were associated with lower disease-free survival. Relapse (HR ¼ 0.119; 95% CI ¼ 0.056-0.250, P ¼ 0.000) and a WT1 expression X0.60% (HR ¼ 2.771; 95% CI ¼ 1.316-5.834, P ¼ 0.007) were associated with lower OS. In conclusion, the WT1 expression level is an independent prognostic factor that can predict clinical outcomes for AL patients after HSCT and provide a guide for suitable interventions.
Introduction
In acute leukemia (AL), particularly in high-risk leukemia, defining a patient as being in credible remission requires morphological analysis and a lack of disease evidence at the submicroscopic level. Such evaluations are particularly important following allogeneic hematopoietic SCT (allo-HSCT), which provides a potentially curative approach for AL. Early detection of relapse by monitoring minimal residual disease (MRD) is useful for guiding appropriate interventions that could aid in preventing hematological relapse. Accumulating evidence has suggested that the Wilms' tumor gene 1 (WT1), which is highly expressed in various types of AL, could serve as a useful marker for monitoring MRD. 1, 2 For subtypes of AL without specific biomarkers, such as BCR/ABL and AML1/ETO, the ubiquitously expressed WT1 gene would be more useful for monitoring MRD. WT1 expression increases significantly during relapse compared with levels at the time of diagnosis. Following HSCT, WT1 expression decreases in the BM. These features help give the WT1 transcript assay a high degree of sensitivity following HSCT. 3 To date, most studies have focused on the prognostic value of WT1 during induction or consolidation therapy, including evaluating WT1 levels before allo-HSCT, and possible associations with transplant outcomes [4] [5] [6] [7] There are relatively few studies that have focused on the impact of monitoring WT1 expression after HSCT. In addition, there are almost no large-scale studies evaluating WT1, and researchers still dispute whether WT1 should be regarded as an independent prognostic factor of clinical outcome following HSCT. [8] [9] [10] [11] Despite the majority of studies conceding the predictive value of WT1, few decisions concerning therapeutic interventions are based on WT1 expression levels.
The aim of this study was to investigate whether a quantitative evaluation of WT1 expression could provide a useful method for monitoring early relapse of AL following allo-HSCT. We dynamically measured the WT1 expression levels of 138 AL patients at precise and sequential time points using real-time quantitative PCR (RQ-PCR). We also analyzed the relationship between the WT1 value and the probability of relapse after HSCT. Finally, we determined the preliminary cutoff levels of WT1 that could be used to direct the suitable interventions.
Patients and methods

Patients
Between May 2006 and March 2008, we enrolled 138 AL patients treated with allo-HSCT at the Peking University Institute of Hematology. A total of 780 BM samples from these patients were collected from both before and after the allo-HSCT. All patients provided informed consent for treatment under a protocol reviewed and approved by Peking University Institute of Hematology. The characteristics of the patients and transplantations are summarized in Table 1 .
Transplant protocols
All patients in this study received myeloablative conditioning regimens. The conditioning therapy was all BU/CY based (4 mg/kg per day BU administered orally for 3 days and 1.8 g/m 2 per day CY i.v. for 2 days) with the addition of one dose of semustine (250 mg/m 2 orally) for all patients and a single dose of cytarabine (2 g/m 2 per day i.v.) for patients who had a matched sibling. HLA mismatched, unrelated matched and cord-blood HSCT patients were also given cytarabine (4 g/m 2 per day) for 2 days and antithymocyte globulin (2.5 mg/kg per day, antithymocyte globulin, SangStat, Lyon, France) i.v. for 4 consecutive days. Prophylaxis against GVHD included treatment with CsA and short-term MTX along with mycophenolate mofetil. CsA (2.5 mg/kg) was started i.v. on day À9. Mycophenolate mofetil was administered orally (0.5 g every 12 h) from day 9 before the transplantation to day 30 after the transplantation. At 30 days after the transplantation, 0.25 g mycophenolate mofetil was given every 12 h for 1-2 months. MXT (15 mg/m 2 ) was administered i.v. on day 1, and 10 mg/m 2 MTX was given on days 3, 6 and 11 after transplantation. For patients receiving cord blood transplants, short-course methylprednisolone was used for GVHD immunoprophylaxis. Immunosuppression regimens were discontinued for all patients who had an AL relapse or a detected MRD (including flow cytometry, WT1 or other AL-related gene expression) while still taking any immunosuppressive agents.
Sample preparation
In total, 780 BM samples from patients were obtained for the investigation of MRD after HSCT. The MRD time points that we monitored included þ 1 month, þ 2 months, þ 3 months, þ 6 months, þ 9 months, þ 12 months and at every 6 months thereafter. More frequent MRD monitoring was carried out in some patients depending on their individual condition.
RNA extraction, cDNA synthesis and RQ-PCR Mononuclear cells were isolated from BM samples by Ficoll-Hypaque gradient centrifugation. TRIzol reagent (Invitrogen, Carlsbad, CA, USA) was used to extract total RNA according to the manufacturer's instructions. Random hexamer primers and Moloney murine leukemia virus reverse transcriptase were used to transcribe RNA into cDNA.
We used TaqMan-based RQ-PCR technology, and all PCR reactions and fluorescence measurements were performed using an ABI PRISM 7500 real-time PCR system (PE Applied Biosystems, Foster City, CA, USA). We selected ABL as a control gene to compensate for the variations in quality and quantity of the RNA and cDNA. The primers and probe for ABL were based on a report of the Europe against Cancer Program.
12, 13 The primers and probe used for WT1 detection were based on a report by Tamaki et al. 14 The PCR reaction mixture contained 10 mL of 2 Â TaqMan Universal PCR Master Mix (PE Applied Biosystems), 300 nM of each primer, 200 nM of probe (100 nM for AML1/ETO) and 2 mL of cDNA in a total volume of 20 mL. All PCR was performed under the following conditions: 50 1C for 2 min, 95 1C for 10 min, and 40 cycles of 95 1C for 15 s and 62 1C for 1 min. Each PCR run included a negative control (H 2 O), a positive control and a set of serial dilutions of ABL plasmids. The assays were validated with serially diluted cDNA from K562 cells (10 0 to 10 6 ). The construction of ABL plasmid calibrators was performed as previously described. 15 Any sample with o3 Â 10 4 copies of ABL was regarded as poor quality and excluded from the test. The experiments were performed in duplicate. The transcript level was calculated as a percentage of the target transcript copies/ABL copies. A WT1 transcript level o0.60% was defined as negative.
Study definitions
The first day of stem cell infusion was defined as 'day 01', and all days after the last stem cell infusion were recorded by the day number and preceded by ' þ '. Neutrophil engraftment was defined as an ANC X0.5 Â 10 9 /L for 3 consecutive days. Platelet engraftment was defined as X20 Â 10 9 /L for 7 consecutive days without platelet transfusion. The diagnosis and grading of GVHD was established based on published criteria. 16, 17 CR was defined as BM blasts o5%, an absence of blasts with Auer rods, an absence of extramedullary disease, an ANC 41.0 Â 10 9 /L, a platelet count 4100 Â 10 9 /L and independence of red cell transfusions. PR includes all the hematological criteria of The role of WT1 after HSCT X-S Zhao et al CR as well as a BM blast percentage from 5 to 20% and a decrease of pretreatment BM blast percentage by at least 50%. The patient was classified as no remission if they did not achieve either of the above standards (that is, CR or PR). 18 Hematological relapse was defined by the reappearance of blasts in the peripheral blood or by an unattained CR following a course of standard antileukemia therapy, in which BM was infiltrated with 45%, but o20%, of blasts in a representative smear. Relapse rate was defined as the probability of leukemia recurrence. OS was calculated from the date of transplantation until death or last observation of patient life. Disease-free survival (DFS) was defined as the probability of being alive and free of disease at any point in time. The intervening measure was defined as receiving a modified donor lymphocyte infusion and the occurrence of acute GVHD through those intervention measures including IL-2. The modified donor lymphocyte infusion (DLI) protocol included two elements: (1) the collection of granulocyte-colony stimulating factor-primed peripheral blood hematopoietic stem cells instead of unprimed donor lymphocyte harvests, and (2) the use of short-term immunosuppressive agents for the prevention of GVHD after DLI. The protocol details have been described by Huang et al. 19 The intervening measure was applied based on the risk stratification of the disease, the level of WT1 expression or the results of other MRD examinations (for example, flow cytometry, AML1/ETO and BCR/ABL) in patients of group 3 and 4.
Statistical analysis
The reference date of 31 May 2010, was used to define the end of follow-up. Disease-free state and OS were calculated according to Kaplan-Meier statistics. Differences in DFS and OS between groups were calculated using the log-rank test. Receiver-operating characteristic (ROC) analysis was performed using SPSS 16.0 software (SPSS Inc., Chicago, IL, USA). A two-sided P-value of 0.05 was regarded as significant. To test the independence of DFS predictive factors, multivariate Cox regression analysis was applied. The independence of categorical parameters was calculated using the w 2 -test or Fisher's exact test, and the distribution of continuous variables was calculated using the MannWhitney U-test.
Results
General patient information
All patients achieved neutrophil engraftment at a mean time of þ 13 days (the range was þ 10-25). Seven patients achieved platelet engraftment after þ 100 days, and one patient died at þ 8 months before achieving platelet engraftment. Platelet engraftment for the last patients was þ 15 days (the range was þ 8 to 80). By the May 2010 end point, the median follow-up time was 30 months (the range was 2.5-48 months), and a total of 69 patients (50.0%) developed acute GVHD. Three patients could not be evaluated for chronic GVHD because of death before day 100. Among the remaining 135 patients, chronic GVHD developed in 65 patients (47.1%). In all, 23 patients (16.7%) relapsed after transplantation (the median was 9 months, and the range was 2-30 months). A total of 29 patients (21.0%) died due to relapse (n ¼ 15) or other causes of transplantation-related mortality (n ¼ 14: infection, n ¼ 10; cerebral hemorrhage, n ¼ 1; hemorrhage of digestive tract, n ¼ 1; post-transplantation lymphoproliferative disorders, n ¼ 1; and disseminated intravascular coagulation, n ¼ 1).
The expression levels of WT1 gene after HSCT in different groups The expression levels of WT1 gene in patients without relapse and intervention (group 1). A total of 138 patients were divided into four groups based on the clinical outcomes of disease following both HSCT and intervention application. There were 82 patients who did not relapse within the follow-up period and possessed consistent low WT1 gene expression levels following HSCT. These patients were defined as group 1. The median follow-up time for these patients was 30 months (the range was 2.5-48 months). A total of 381 BM samples were collected from this group of patients. The median expression levels of WT1 at þ 1, þ 2, þ 3, þ 6, þ 12, þ 18 and þ 24 months were 0.08% (0.00-0.73%), 0.08% (0.00-0.53%), 0.09% (0.00-0.55%), 0.12% (0.00-0.88%), 0.16% (0.01-0.54%), 0.14% (0.00-0.78%) and 0.15% (0.02-0.37%), respectively ( Figure 1 ). WT1 expression was not significantly different between groups of various time points (P40.05). Among the 381 samples, there were only 8 samples (2.1%) from 8 patients had WT1 expression 40.6% at any time point during follow-up that returned to negative levels on serial monitoring in this group.
There were 26 patients in group 1 who had abnormally increased WT1 expression at the time of diagnosis. Median WT1 expression levels in these 26 patients at þ 1, þ 2, þ 3, þ 6, þ 12, þ 18 and þ 24 months were 0.09% (0.01-0.35%), 0.09% (0.02-0.53%), 0.13% (0.05-0.38%), 0.11% (0.03-0.44%), 0.15% (0.01-0.44%), 0.23% (0.00-0.79%) and 0.16% (0.04-0.37%), respectively. No significant differences were seen among various time points in these Months after HSCT The levels of WT1 expression The role of WT1 after HSCT X-S Zhao et al 26 patients (P40.05). In addition, the 26 patients with increased WT1 expression did not exhibit higher WT1 expression after HSCT compared with the rest of the patients in group 1 (P40.05).
WT1 gene expression levels in relapsed patients without any interventions (group 2) A total of 11 patients in group 2 relapsed at a median of 142 days after HSCT (the range was 60-720 days). They had not received any interventions before hematological relapse for a variety of reasons. A total of 51 BM samples from several time points were collected. The patient WT1 gene expression levels were found to exceed 0.60% at a median of þ 120 days (the range was þ 60 to 720 days) in all 11 patients after HSCT. The elevated expression level of WT1 was 10.12% (the range was 0.94-108.20%). In all, 6 of the 11 patients demonstrated elevated levels at a median of 17 days (the range was 9-120 days) before their hematological relapse, whereas the other 5 patients relapsed and showed increased WT1 expression at the same time. Increased WT1 expression was found within 30 days around relapse in all but one patient who had ALL. The WT1 expression in the ALL patient was 1.10% at þ 2 months after HSCT, but it decreased to a normal level (0.29%) by þ 3 months without any intervention.
WT1 gene expression levels in patients without relapse due to interventions (group 3). Group 3 included 33 patients who had demonstrated a recurrence trend after HSCT. After receiving defined interventions, however, they did not experience leukemia relapse. MRD monitoring was performed at designated time points after HSCT in all of the 33 patients, and 20 of them received modified DLI after detection of elevated WT1 gene expression. The median duration between detection of the elevated WT1 and intervention was 30 days (the range was 16-72 days). Among the remaining 13 patients, 5 patients received prophylactic interventions because of the high risk of their primary disease. Because of the detection of MRD (increased AML1/ETO gene expression level, n ¼ 2; positive IgH rearrangement, n ¼ 1; and positive flow cytometry, n ¼ 5) after HSCT, eight patients were administered prophylactic-modified DLI to counteract their high risk of leukemia relapse. Furthermore, the WT1 values of these patients increased in parallel with the MRD parameters. Indeed, WT1 gene expression in these patients was found to exceed 0.60% at a median of þ 120 days (the range was þ 30 to 420 days), and the elevated WT1 expression level was 0.78% (the range was 0.62-20.80%). The WT1 expression level was found to be o2.60% in the majority of the patients in group 3. One patient, however, showed a relatively high level of WT1 expression (20.80%). The WT1 gene expression levels of the 33 patients in group 3 were also monitored after they received modified DLI. A median WT1 expression level of 0.22% (the range was 0.05-0.50%) was observed in 18/20 patients following interventions. The remaining two patients continued to show elevated WT1 expression (9.90 and 3.58%, respectively); however, they died of severe infection before hematological relapse. The WT1 expression levels before and after intervention was significantly different (P ¼ 0.002). In addition, the WT1 expression levels were also significantly different between groups 2 and 3 (P ¼ 0.001), although no significant difference was seen between the two groups after HSCT (P40.05).
WT1 gene expression levels in patients who relapsed despite receiving interventions (group 4). There were a total 12 patients in group 4, including 2 T-ALL patients and 4 patients, who did not reach CR at the time of transplant. Elevated WT1 expression was found in all 12 patients with a median time of 165 days after HSCT (the range was 30-480 days). The median level of elevated WT1 gene expression was 1.60% (the range was 0.67-72.00%). These 12 patients were subjected to modified DLI as initially planned; however, 10 of the patients continued to show increased WT1 expression (the median was 9.00% and the range was 2.80-45.70%). WT1 expression in the other two patients dropped below 0.60% after DLI. They displayed a re-rising WT1 expression soon after that followed by hematological relapse.
Relapse and WT1 gene expression level before HSCT
The WT1 values before HSCT were available for 70 out of 138 patients. In all, 22 out of 70 patients showed a WT1 expression level 40.60%, and 7 of these patients relapsed. Only 5 of the remaining 48 patients with normal WT1 expression levels before transplant relapsed after receiving an HSCT. Figure 2 shows the significant difference in the rate of relapse between these two groups of patients (P ¼ 0.019).
Relapse, DFS, OS and the WT1 gene expression level after HSCT
We performed a ROC analysis to investigate the relationship between relapse and the highest expression level of WT1 following HSCT in all patients. The area under the ROC curve value was 0.937 (95% confidence interval (CI) ¼ 0.871-1.004, P ¼ 0.000, Figure 3a) . These results indicate that higher WT1 expression is associated with a greater AL relapse rate for patients following HSCT. Following this analysis, we evaluated the diagnostic accuracy of WT1 expression using various WT1 values as cutoff points. The results indicate that the optimal cutoff point to predict an inevitable relapse is 1.05%. When this tentative cutoff value was used, WT1 expression levels had a sensitivity of 91.3% and specificity of 89.6% on the ROC curve. The high sensitivity and specificity suggest that WT1 expression 41.05% indicates a high probability of relapse after HSCT. Interestingly, Figure 3b shows that 460% of patients with WT1 expression 41.00% ultimately underwent hematological relapse.
The relationship between WT1 expression and DFS was analyzed using a Cox multivariate analysis that considered several variables, including patient age, sex, HLA matching, status of disease before HSCT, WT1 value before transplant, occurrence of acute/chronic GVHD and the highest WT1 level after HSCT. Interestingly, only advanced stages of disease (hazard ratio (HR) ¼ 2.73; 95% CI ¼ 1.337-5.573, P ¼ 0.006) and WT1 expression X0.60% (HR ¼ 4.774; 95% CI ¼ 2.410-9.459, P ¼ 0.000) were associated with lower DFS (Figure 4a ). WT1 expression 41.00% indicated a significantly worse DFS, which can be seen in Figure 4b (P ¼ 0.000).
The Cox multivariate analysis was also performed to investigate the relationship between OS and WT1 expression after HSCT. In addition to the variables mentioned above, hematological relapse after HSCT was also included in the analysis. The results showed that relapse (HR ¼ 0.119; 95% CI ¼ 0.056-0.250, P ¼ 0.000) and WT1 expression X0.60% (HR ¼ 2.771; 95% CI ¼ 1.316-5.834, P ¼ 0.007) were associated with a lower OS. Kaplan-Meier analysis indicated a significant difference in OS when the cutoff value of WT1 expression was 0.60% or 1.00% (P ¼ 0.002 and P ¼ 0.000, respectively; Figure 5 ). Table 2 shows the total number of patients who died during the follow-up period. Except for the comparison of group 1 and group 3 (P ¼ 0.991), Kaplan-Meier analysis demonstrated that there were significant differences in OS between all other groups (Po0.05, Figure 6 ). In agreement with our hypothesis, patients in group 4 demonstrated the lowest OS.
Comparison WT1 with other molecular markers during disease In all, 16 out of 92 AML patients had a molecular marker (13 cases with AML1/ETO, 2 cases with CBFb/MYH11 and 1 case with mixed-lineage leukemia rearrangement). Both WT1 gene expression and the other molecular marker were determined in these patients during follow-up and the data have been compared. The baseline WT1 expression was detectable in all samples even if the expression level of the other molecular marker was below the reportable range.
There was a good concordance between the levels of WT1 and other molecular markers. Figure 7 shows the results of three representative patients during follow-up.
Discussion
The usefulness of the WT1 gene as a 'panleukemic marker' is based on its high prevalence and overexpression during AL. Thus, it is a candidate MRD marker for leukemia in patients, especially for cases that otherwise lack a specific molecular marker. There is still no consensus, however, as to whether WT1 should be regarded as a credible marker for monitoring early relapse after HSCT. These differences in opinion might be because of the various methods used to evaluate WT1. In this study, RQ-PCR was used to determine WT1 expression levels because of its high sensitivity. Using RQ-PCR, Ogawa et al. 10 were the first to demon- strate that WT1 expression could serve as an essential parameter for risk stratification of early relapse after HSCT. Candoni et al. 11 also reported similar results. In this study, the group 1 data revealed a concordance between normal levels of WT1 gene expression and remission status in the patients who maintained a CR after HSCT. Except for eight samples, one of which showed WT1 expression 41.00%, the WT1 levels of BM samples in group 1 patients were o0.60%. Follow-ups of the eight patients that showed higher WT1 expression revealed that WT1 levels quickly returned to normal. Candoni et al. 20 demonstrated that the WT1 levels of all patients in CR remained within the range of normality throughout the follow-up period, and they were consistent with morphological BM analysis, molecular-specific markers and full donor chimerism. A similar result was also obtained in our study. Indeed, the results of this study suggest that consistently low expression of WT1 after HSCT indicates a relatively low risk of relapse in AL regardless of whether the WT1 value was abnormal at the time of the initial diagnosis. This is in line with the findings of Busse et al., 21 which showed that WT1 expression levels at diagnosis have no influence on DFS.
The discrepancy of outcomes between group 2 and group 3 further support the prognostic value of WT1 expression levels following HSCT. Although there were no obvious differences in the initial measurements of WT1 expression, WT1 immediately following HSCT was much higher in group 2 compared with group 3. These results might be interpreted to suggest that hematological relapse could be prevented if suitable interventions are given according to MRD monitoring based primarily on slightly elevated WT1 expression. Furthermore, the WT1 values of eight patients who had received interventions for reasons other than WT1 levels also increased in parallel with their MRD-specific markers. Some previous reports have confirmed the expression consistency between the WT1 gene and other specific leukemia genes, such as AML1/ETO, CBFb/ MYH11 and BCR/ABL. 22, 23 Thus, the WT1 expression level could be regarded as a credible MRD marker that might guide well-timed intervention after HSCT, which could prevent relapse. The WT1 expression in group 3, however, was also able to reflect the therapeutic effects of our preemptive treatment (that is, an obvious decrease in WT1 expression could always be observed following the effective intervention). The patients in group 2 underwent hematological relapse, which may have resulted from high levels of WT1 expression at the first instance of abnormality. These patients likely relapsed because they did not receive an intervention in a timely manner. The OS of patients in group 2, however, was not as disappointing as that of group 4, which could be because the WT1 values of patients in group 2 returned to normal after receiving chemotherapy or modified DLI, whereas WT1 levels in most patients in group 4 did not. In addition, the similar OS of group 1 and group 3 implies that the outcomes of AL patients with relapse risk after HSCT could be improved by WT1-based preemptive treatment. The present data further confirmed the indicative value of WT1 expression after HSCT. The difference between group 4 and groups 2 and 3 was the continuously elevated WT1 levels, even after the initiation of preventative intervention. Because group 4 included two T-ALL patients and four patients who did not reach CR at the time of transplantation, we speculated that the patients of this group might have particular biological characteristics that could explain their outcomes and WT1 levels. Ogawa et al. 10 demonstrated that no patients with a WT1 expression doubling time of less than 13 days responded to the immunomodulation therapy, whereas five of the seven patients with a WT1 doubling time of 13 days or greater responded to the therapy. Lin et al. 24 reported similar results for patients with CML. Indeed, patients with quickly doubling numbers of BCR/ABL transcripts were less likely to respond to DLI than patients with a long doubling time. Patients with longer doubling times may have some residual graft-vs-leukemia effect that slows the speed of relapse, and this graft-vs-leukemia effect can be reinforced by the withdrawal of immunosuppressive agents or DLI. We investigated prognostic value of WT1 gene expression for predicting AL relapse following HSCT. Most of the previous studies on the prognostic value of WT1 have demonstrated that the WT1 level after induction of chemotherapy or before transplant, but not at the time of diagnosis, has predictive value concerning the clinical outcomes of AL patients. 4, 25 For example, Jacobsohn et al.
25 demonstrated that the pretransplant WT1 level was the only significant prognostic factor for determining differences in EFS. Consistent with their results, the data of our study also showed that a WT1 level 40.60% before HSCT predicted a higher risk of relapse. The exact role of WT1 expression after HSCT, however, is still a matter of debate. Regardless of whether the patients received interventions, ROC analysis indicated that WT1 expression 41.00% was associated with a high risk of hematological relapse. Although we set the WT1 threshold value at 0.60%, the ROC analysis implied that a WT1 level 41.00% would be more likely to indicate relapse. We previously conducted a small-scale study (n ¼ 31) that demonstrated that 1.00% would be a more suitable cutoff value for determining the ability of WT1 expression to predict leukemia relapse. 26 The present study confirmed the previous conclusion. Doctors still do not know whether we should give an intervention once WT1 expression reaches between 0.60 and 1.00% after HSCT, especially when DLI is used as the measure of intervention, which might be followed by severe GVHD or pancytopenia. The results of Kaplan-Meier and multivariate analysis on DFS and OS could potentially answer this question. When either 0.60 or 1.00% was defined as the cutoff value of WT1 expression, we found significant differences in DFS and OS between two groups of patients. Greater than 0.60% WT1 expression after HSCT has been shown to be an independent risk factor of DFS and OS; however, Cox multivariate analysis did not reveal that 40.60% WT1 expression could be an independent prognostic factor for DFS or OS in AL patients before transplant. A combination of the above evidence supports the notion that choosing 0.60% as the threshold value of WT1 is reasonable for clinical applications. Dynamically monitoring the expression level of WT1 after HSCT, however, is more important for determining whether intensive intervention should be performed.
In summary, our data indicate that WT1 expression is a valuable and essential marker for MRD monitoring following HSCT. Indeed, the overexpression of WT1 during follow-up is highly predictive of leukemia relapse. Although our results need to be confirmed in a large-scale, prospective study, we consider the current qualitative assessment of WT1 expression to be a very useful test for the prevention and management of early relapse in AL patients following HSCT. Further research should focus on the personalization of MRD monitoring based on WT1 quantification and other methods for suitable intervention after HSCT, which could improve clinical outcomes of AL patients.
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